Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/30/2009

009, and $0.5 million in earn-out payments under the Company's agreement with DFB Biotech Inc. and its affiliates.

Research and development expenses for the fourth quarter of 2008 were $0.2 million, compared to $1.9 million for the same period in 2007. For the year ended December 31, 2008, research and development expenses were $0.4 million, compared to $2.5 million in 2007. The decreases in research and development expenses were primarily due to lower third-party development costs in the 2008 periods.

General and administrative expenses for the fourth quarter of 2008 totaled $1.4 million, compared to $0.6 million for the same period in 2007. For the year ended December 31, 2008, general and administrative expenses were $4.2 million, compared to $3.5 million in 2007. The increases in general and administrative expenses were primarily due to increases in stock-based compensation expense, and legal and other third party fees related to the modification of the Company's agreement with Auxilium in connection with the Pfizer transaction.

As of December 31, 2008, BioSpecifics held cash, cash equivalents and short-term investments, of $4.4 million, compared to $1.0 million on December 31, 2007. This does not include the $6.375 million payment that was received by BioSpecifics from Auxilium on January 30, 2009.

2008 Corporate Highlights

In June 2008, BioSpecifics' partner Auxilium announced positive top-line efficacy and safety results from the CORD I and CORD II phase III clinical trials for XIAFLEX(TM) in the treatment of Dupuytren's disease.

In September 2008, BioSpecifics announced an agreement to significantly improve the deal terms related to its future royalty obligations to a third party for XIAFLEX(TM) for Peyronie's disease by buying down its future royalty obligations with a one-time cash payment. BioSpecifics made this strategic decision based on the
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
2. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
5. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
6. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
9. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
11. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2
... N.C. , May 13 Chimerix, Inc., ... the commencement of a first-in-human study of CMX157, a ... in vitro activity against both tenofovir-sensitive and tenofovir-resistant ... increase efficacy and decrease toxicity as compared to tenofovir, ...
... LA JOLLA, Calif. , May 13 Transdel ... focused on developing topically administered products using its proprietary transdermal ... March 31, 2010 .  The Company also highlighted recent ... , ...
... , DUBLIN and PHILADELPHIA , ... ), the global specialty biopharmaceutical company,announces that its subsidiary Shire LLC has ... Delaware against Actavis Elizabeth LLC and,Actavis Inc. (collectively "Actavis") for the ... and 6,811,794,(the ,794 patent). , , ...
Cached Biology Technology:Chimerix Initiates Phase 1 Study of CMX157 2Chimerix Initiates Phase 1 Study of CMX157 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 2Transdel Pharmaceuticals Reports First Quarter 2010 Results 3Transdel Pharmaceuticals Reports First Quarter 2010 Results 4Transdel Pharmaceuticals Reports First Quarter 2010 Results 5INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 2INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. 3
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) and ... Medicine today announced they will be partnering with ... drugs. , Under the agreement with Shanghai-based HD ... the costs and risks of discovery and development ... own any intellectual property and commercialization rights to ...
(Date:7/10/2014)... 2014 Amidst the astounding complexity of the billions ... the brain, how do nerve cells decide how far ... do they coordinate these events within the developing brain? ... campus of The Scripps Research Institute (TSRI) have shed ... particular protein plays a far more sophisticated role in ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2Scripps Florida scientists shed new light on nerve cell growth 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
... include: Microarray hybridization chamber assembly (1 ... clamp, thumbscrew) Microarray chamber user guide ... intended to be cleaned and reused. The ... Catalog Oligo Microarray kits and all custom ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
Biology Products: